High expression of CD59 and CD55 on benign and malignant plasma cells

被引：12

作者：

Alcindor, T

Kimlinger, T

Witzig, TE

机构：

[1] McGill Univ, Dept Oncol, Montreal, PQ H3A 2T5, Canada

[2] McGill Univ, Dept Med, Div Med Oncol, Montreal, PQ H3A 2T5, Canada

[3] Mayo Clin & Mayo Fdn, Dept Internal Med, Rochester, MN 55905 USA

[4] Mayo Clin & Mayo Fdn, Div Hematol, Rochester, MN 55905 USA

来源：

LEUKEMIA & LYMPHOMA | 2006年 / 47卷 / 05期

关键词：

D O I：

10.1080/10428190500467784

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In summary, our study reveals a relatively high expression of complement regulatory proteins on the surface of plasma cells, which appears to be a constitutive feature of these cells, rather than a specific change induced by a malignant state. Further efforts will aim at establishing a correlation between CD55 and CD59 expression levels and in vitro and in vivo resistance to rituximab. © 2006 Taylor & Francis.

引用

页码：919 / 921

页数：3

共 13 条

[1] Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin [J].

Ghetie, MA ;

Bright, H ;

Vitetta, ES .

BLOOD, 2001, 97 (05) :1392-1398

[2]

Golay J, 2000, BLOOD, V95, P3900

[3]

Harjunpää A, 2000, SCAND J IMMUNOL, V51, P634

[4] Monoclonal antibody therapy in the treatment of non-Hodgkin lymphoma [J].

McCune, SL ;

Gockerman, JP ;

Rizzieri, DA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (10) :1149-1152

[5]

MINGES WH, 2002, J IMMUNOL, V169, P4213

[6] EXPRESSION OF DECAY-ACCELERATING FACTOR AND CD59 IN LYMPHOCYTE SUBSETS OF HEALTHY-INDIVIDUALS AND PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA PATIENTS [J].

NAGAKURA, S ;

NAKAKUMA, H ;

HORIKAWA, K ;

HIDAKA, M ;

KAGIMOTO, T ;

KAWAKITA, M ;

TOMITA, M ;

TAKATSUKI, K .

AMERICAN JOURNAL OF HEMATOLOGY, 1993, 43 (01) :14-18

[7]

NICHOLSONWELLER A, 1985, BLOOD, V65, P1237

[8]

REFF ME, 1994, BLOOD, V83, P435

[9]

Treon SP, 2000, SEMIN ONCOL, V27, P598

[10] CD20-directed serotherapy in patients with multiple myeloma: Biologic considerations and therapeutic applications [J].

Treon, SP ;

Pilarski, TM ;

Belch, TR ;

Kelliher, A ;

Preffer, FI ;

Shima, Y ;

Mitsiades, CS ;

Mitsiades, NS ;

Szczepek, AJ ;

Ellman, L ;

Harmon, D ;

Grossbard, ML ;

Anderson, KC .

JOURNAL OF IMMUNOTHERAPY, 2002, 25 (01) :72-81

← 1 2 →